Will an emerging cancer therapy that links potent drugs to tumor-seekers take the place of standard chemotherapy?
by Elizabeth Dougherty

Eric Winer, MD (left), has been leading clinical trials at DF/BWCC focusing on the antibody-drug conjugate T-DM1.

Sarah Merchant was working as a Web designer in Boston when, at age 28, she was diagnosed with stage 4 metastatic breast cancer. Surgery, radiation, and a series of chemotherapy regimens followed, as did nerve damage, hair loss, and a general decline in her health.
Then Merchant heard about T-DM1, a trial drug promising the effectiveness of chemotherapy without the toxicity. “I wanted to get into that …